JW Therapeutics has received approval from the National Medical Products Administration of China to conduct a Phase 1 / 2 clinical trial of its CAR T-cell therapy, relmacabtagene autoleucel (relma-cel), for people with moderate to severe and/or treatment-resistant lupus. CAR T-cells are genetically altered T-cells that play a role in the immune response. Scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them to create CAR-T cells.




Article Credit: Lupus Foundation of America | lupus.org